Compared side by side

Orforglipron vs tirzepatide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Orforglipron is a small molecule (not a peptide) that acts on one receptor, GLP-1, taken as a daily tablet with or without food; tirzepatide is a weekly shot that activates the GLP-1 and GIP receptors. Both are FDA-approved for weight management, orforglipron as Foundayo since April 2026 and tirzepatide as Zepbound. In their own trials, orforglipron’s top dose averaged about 11% weight loss at 72 weeks, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).

Side by side

ComparedOrforglipronTirzepatide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asFoundayo, LY3502970, OrfoMounjaro, Zepbound, LY3298176
What it isA GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management.The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
How it worksSmall-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily.Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
Commonly reportedThe easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial.Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
Studied rangeFDA label: 0.8–17.2 mg, starting dose 0.8 mg.FDA label: 2.5–15 mg, starting dose 2.5 mg.
How oftenDailyWeekly
Half-life~29–49 hours (FDA label; steady levels after about a week of daily tablets)~5 days (FDA label)
RouteOral tabletSubQ injection
Typical runFDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off.FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burpingNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking orforglipron or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Orforglipron

  • Day 1–30 · 0.8 mg The 0.8 mg start
  • Day 31–60 · 2.5 mg 2.5 mg, the second step
  • Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
  • Day 91+ · 9 mg 9 mg, an optional step
  • Day 121+ · 14.5 mg 14.5 mg, the step before the top
  • Day 151+ · 17.2 mg 17.2 mg, the top dose

Every card for orforglipron, with its sources

Tirzepatide

  • Day 1–28 · 2.5 mg Getting your gut acclimated
  • Day 29–56 · 5 mg First therapeutic dose — weight drops
  • Day 57–112 · 7.5 mg Dual agonism in full effect
  • Day 113–168 · 12.5 mg Max titration reached
  • Day 169–504 Weeks 24 to 72: where most people plateau
  • Day 365+ A maintenance medication, not a course

Every card for tirzepatide, with its sources

Questions people ask

How long do orforglipron and tirzepatide last?

The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets). The half-life of tirzepatide is ~5 days (FDA label).

How often are orforglipron and tirzepatide taken?

Orforglipron: daily. Route: Oral tablet. Tirzepatide: weekly. Route: SubQ injection.

How are orforglipron and tirzepatide dosed in research?

The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose. The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose.

What are the common side effects of orforglipron and tirzepatide?

For orforglipron, the library lists: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping. For tirzepatide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue.

Each one in full

Track it in the app

PepVault for iPhone

Taking orforglipron or tirzepatide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo